You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of children with AOM

From: Resistant Streptococcus pneumoniae strains in children with acute otitis media– high risk of persistent colonization after treatment

Characteristics Category Total (%) n = 62 No of SP positive samples (%)
MEF during AOM NP/OP during AOM NP/OP during PT visitc
Age (yr) 1–2 20 (32.3) 6 (30.0) 5 (25.0) 5 (25.0)
3–5 31 (50.0) 10 (32.3) 11 (35.5) 5 (21.7)
≥6 11 (17.7) 1 (9.1) 1 (9.1) 1 (10.0)
Sex Male 38 (61.3) 13 (34.2) 12 (31.6) 8 (24.2)
Female 24 (38.7) 4 (16.7) 5 (20.8) 3 (15.0)
Sibling possessing No 21 (33.9) 6 (28.6) 5 (23.8) 4 (23.5)
1 30 (48.4) 11 (36.7) 11 (36.7) 7 (25.9)
≥2 11 (17.7) 0 (0.0) 1 (9.1) 0 (0.0)
DCC/school attendance   45 (72.6) 12 (26.7) 12 (26.7) 7 (18.9)
Laterality Unilateral 25 (40.3) 5 (20.0) 5 (20.0) 2 (9.1)
Bilateral 37 (59.7) 12 (32.4) 12 (32.4) 9 (29.0)
Category of AOM TF 37 (59.7) 10 (27.0) 11 (29.7) 7 (24.1)
R 6 (9.7) 3 (50.0) 1 (16.7) 1 (16.7)
N 19 (30.7) 4 (21.1) 5 (26.3) 3 (16.7)
CRP (mg/L) (median, range)a   2.27 (0.01–46.9) 3.6 (0.15–12.0) 4.8 (0.05–19.5) NA
WBC (G/L) (median, range)b   14.0 (5.4–33.0) 20.4 (7.8–30.2) 17.6 (7.8–30.2) NA
Ongoing antibiotic therapy at the admission to hospital No 46 (74.2) 15 (32.6) 15 (32.6) 10 (24.4)
Yes 16 (25.8) 2 (12.5) 2 (12.5) 1 (8.3)
Antibiotic therapy at the hospital AM/AMC 11 (17.7) 3 (27.3) 1 (9.1) 1 (11.1)
CXM 21 (33.9) 4 (19.1) 5 (23.8) 4 (20.0)
CTX/CAZ 28 (45.2) 10 (35.7) 11 (39.3) 6 (26.1)
CLI 2 (3.2) 0 (0.0) 0 (0.0) 0 (0.0)
Antipneumococcal vaccination   13 (21.0) 1 (7.7) 0 (0.0) 0 (0.0)
AntiHib vaccination   58 (93.5) 17 (29.3) 17 (29.3) 11 (22.5)
  1. adata available for 50 persons; bdata available for 61 persons; cdata available for 53 persons; R recurrent AOM, TF treatment failure AOM, N new case AOM, MEF middle ear fluid, DCC day care center, CRP C-reactive protein, WBC white blood cells, PT visit post-treatment visit, Hib Haemophilus influenzae type b, NP nasopharyngeal, OP oropharyngeal, AM/AMC amoxicillin or amoxicillin-clavulanic acid, CXM cefuroxime, CTX/CAZ cefotaxime or ceftazidime, CLI clindamicin, NA not applicable